Research map: Adapted XBB.1.5 vaccine effectiveness against severe COVID-19 outcomes among immunocompromised persons in 2023–24 in six European countries: a VEBIS-EHR network study

Back to the article

Papers in this map

  1. Quantifying heterogeneity in a meta‐analysis · Julian P. T. Higgins · 2002 · 37571 citations · Cited by this paper
  2. Epidemiological characteristics of varicella and factors associated with breakthrough varicella among children aged 0–14 years in Jiangsu Province, China · 2026 · Related
  3. Consensus Values and Weighting Factors · Robert C Paule · 1982 · 586 citations · Cited by this paper
  4. Evaluating the socioeconomic value of adult respiratory immunization in Spain: a benefit–cost analysis · 2026 · Related
  5. Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study · Rachael A Evans · 2023 · 210 citations · Cited by this paper
  6. Progress toward an Epstein-Barr virus vaccine · 2026 · Related
  7. Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023–January 2024 · Ruth Link‐Gelles · 2024 · 173 citations · Cited by this paper
  8. Evaluating the societal value of adult respiratory vaccination in Sweden: a benefit–cost analysis · 2026 · Related
  9. COVID-19 vaccine effectiveness among immunocompromised populations: a targeted literature review of real-world studies · Manuela Di Fusco · 2022 · 124 citations · Cited by this paper
  10. Pneumococcal conjugate vaccines in older adults and immunocompromised individuals · 2025 · Related
  11. Interim Estimates of 2024–2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years — VISION and IVY Networks, September 2024–January 2025 · Ruth Link‐Gelles · 2025 · 90 citations · Cited by this paper
  12. Healthcare professionals’ perspectives and preferences regarding adolescent meningococcal disease vaccination in the United States · 2026 · Related
  13. An Evidence-Based Approach to Covid-19 Vaccination · Vinay K. Prasad · 2025 · 79 citations · Cited by this paper
  14. Whole cell and acellular pertussis vaccines - rethinking the evidence · 2026 · Related
  15. Impact of COVID-19 on total excess mortality and geographic disparities in Europe, 2020–2023: a spatio-temporal analysis · Margherita Pizzato · 2024 · 68 citations · Cited by this paper
  16. The impact of a pneumococcal vaccination on disease activity in children and adolescents with inflammatory bowel disease: a 2-year prospective study · 2026 · Related
  17. Variant-adapted COVID-19 booster vaccines · Florian Krammer · 2023 · 46 citations · Cited by this paper
  18. Not so cold! Improving the thermostability of mRNA vaccines · 2025 · Related
  19. COVID-19: From emerging variants to vaccination · Thilini Hemali Senevirathne · 2023 · 40 citations · Cited by this paper
  20. Influenza vaccination willingness and influencing factors among older adults in Chongqing China: a cross-sectional study based on the WHO’s behavioral and social drivers of vaccination framework · 2026 · Related
  21. Immunocompromised individuals are at increased risk of COVID‐19 breakthrough infection, hospitalization, and death in the post‐vaccination era: A systematic review · Jola Bytyci · 2024 · 39 citations · Cited by this paper
  22. Effectiveness of XBB.1.5 Monovalent COVID‐19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS‐EHR Network Study · Susana Monge · 2024 · 36 citations · Cited by this paper
  23. COVID-19 Vaccine Booster Strategies in Light of Emerging Viral Variants: Frequency, Timing, and Target Groups · Sherrie L. Kelly · 2022 · 30 citations · Cited by this paper
  24. Immune escape and attenuated severity associated with the SARS-CoV-2 BA.2.86/JN.1 lineage · Joseph A. Lewnard · 2024 · 29 citations · Cited by this paper
  25. Immunocompromised individuals remain at risk of COVID-19: 2023 results from the observational INFORM study · Jennifer Kathleen Quint · 2025 · 26 citations · Cited by this paper
  26. Estimated 2023-2024 COVID-19 Vaccine Effectiveness in Adults · Ruth Link‐Gelles · 2025 · 26 citations · Cited by this paper
  27. Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during the Omicron BA.2.86/JN.1 period among older adults in seven European countries: A VEBIS-EHR network study · Baltazar Nunes · 2024 · 25 citations · Cited by this paper
  28. Comparison of COVID-19 and Influenza-Related Outcomes in the United States during Fall–Winter 2022–2023: A Cross-Sectional Retrospective Study · Hagit Kopel · 2024 · 21 citations · Cited by this paper
  29. Benefit–risk evaluation of COVID-19 vaccination in special population groups of interest · Paul A. H. Moss · 2022 · 17 citations · Cited by this paper
  30. Uptake, effectiveness and safety of COVID-19 vaccines in individuals at clinical risk due to immunosuppressive drug therapy or transplantation procedures: a population-based cohort study in England · Daniel Tzu-Hsuan Chen · 2024 · 15 citations · Cited by this paper
  31. EXAMINING BIAS FROM DIFFERENTIAL DEPLETION OF SUSCEPTIBLES IN VACCINE EFFECTIVENESS ESTIMATES IN SETTINGS OF WANING · Rebecca J. Kahn · 2023 · 13 citations · Cited by this paper
  32. Early COVID‐19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023–January 2024 · Liliana Antunes · 2024 · 13 citations · Cited by this paper
  33. Navigating the Evolving Landscape of COVID-19: Strategies to Increase Vaccine Confidence and Improve Vaccination Rates in the United States · James A. Mansi · 2024 · 10 citations · Cited by this paper
  34. COVID-19: vaccination, therapeutics and a review of the science and public health · Sanjit Kumar Shah · 2024 · 8 citations · Cited by this paper
  35. Covid-19: Are we seeing a summer wave? · Elisabeth Mahase · 2024 · 7 citations · Cited by this paper
  36. Comparative effectiveness of bivalent BA.4–5 or BA.1 mRNA booster vaccines among immunocompromised individuals across three Nordic countries: A nationwide cohort study · Mie Agermose Gram · 2024 · 6 citations · Cited by this paper
  37. Assessing the impact of SARS-CoV-2 on influenza-like illness surveillance trends in the community during the 2023/2024 winter in England · Jonathon Mellor · 2024 · 3 citations · Cited by this paper
  38. Interim effectiveness of the updated 2023-2024 COVID-19 vaccines in adults with immunocompromizing conditions · Marcus R. Pereira · 2024 · 1 citation · Cited by this paper
  39. Untitled · Cited by this paper

Source: OpenAlex (CC0)